Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32499299)

  • 1. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
    Abbott JM; Zhou Q; Esquer H; Pike L; Broneske TP; Rinaldetti S; Abraham AD; Ramirez DA; Lunghofer PJ; Pitts TM; Regan DP; Tan AC; Gustafson DL; Messersmith WA; LaBarbera DV
    Mol Cancer Ther; 2020 Aug; 19(8):1598-1612. PubMed ID: 32499299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L.
    Prigaro BJ; Esquer H; Zhou Q; Pike LA; Awolade P; Lai XH; Abraham AD; Abbott JM; Matter B; Kompella UB; Messersmith WA; Gustafson DL; LaBarbera DV
    J Med Chem; 2022 Mar; 65(5):3943-3961. PubMed ID: 35192363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
    Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
    Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHD1L promotes tumor progression and predicts survival in colorectal carcinoma.
    Ji X; Li J; Zhu L; Cai J; Zhang J; Qu Y; Zhang H; Liu B; Zhao R; Zhu Z
    J Surg Res; 2013 Nov; 185(1):84-91. PubMed ID: 23746766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromodomain Helicase/ATPase DNA-Binding Protein 1-Like Gene (CHD1L) Expression and Implications for Invasion and Metastasis of Breast Cancer.
    Mu QJ; Li HL; Yao Y; Liu SC; Yin CG; Ma XZ
    PLoS One; 2015; 10(11):e0143030. PubMed ID: 26599012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2.
    He WP; Guo YY; Yang GP; Lai HL; Sun TT; Zhang ZW; Ouyang LL; Zheng Y; Tian LM; Li XH; You ZS; Xie D; Yang GF
    Int J Med Sci; 2020; 17(15):2387-2395. PubMed ID: 32922205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
    Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
    Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients.
    Chen L; Chan TH; Yuan YF; Hu L; Huang J; Ma S; Wang J; Dong SS; Tang KH; Xie D; Li Y; Guan XY
    J Clin Invest; 2010 Apr; 120(4):1178-91. PubMed ID: 20335658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.
    Abraham AD; Esquer H; Zhou Q; Tomlinson N; Hamill BD; Abbott JM; Li L; Pike LA; Rinaldetti S; Ramirez DA; Lunghofer PJ; Gomez JD; Schaack J; Nemkov T; D'Alessandro A; Hansen KC; Gustafson DL; Messersmith WA; LaBarbera DV
    J Med Chem; 2019 Nov; 62(22):10182-10203. PubMed ID: 31675229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.
    Clune S; Awolade P; Zhou Q; Esquer H; Matter B; Kearns JT; Kellett T; Akintayo DC; Kompella UB; LaBarbera DV
    Biomed Pharmacother; 2024 Jan; 170():116037. PubMed ID: 38128184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer.
    Liu C; Fu X; Zhong Z; Zhang J; Mou H; Wu Q; Sheng T; Huang B; Zou Y
    Dig Dis Sci; 2017 Sep; 62(9):2376-2385. PubMed ID: 28646284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pien Tze Huang inhibits liver metastasis by targeting TGF-β signaling in an orthotopic model of colorectal cancer.
    Lin W; Zhuang Q; Zheng L; Cao Z; Shen A; Li Q; Fu C; Feng J; Peng J
    Oncol Rep; 2015 Apr; 33(4):1922-8. PubMed ID: 25653118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1.
    Juneja M; Kobelt D; Walther W; Voss C; Smith J; Specker E; Neuenschwander M; Gohlke BO; Dahlmann M; Radetzki S; Preissner R; von Kries JP; Schlag PM; Stein U
    PLoS Biol; 2017 Jun; 15(6):e2000784. PubMed ID: 28570591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse LEF/TCF Expression in Human Colorectal Cancer Correlates with Altered Wnt-Regulated Transcriptome in a Meta-Analysis of Patient Biopsies.
    Mayer CD; Giclais SM; Alsehly F; Hoppler S
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32403323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
    Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
    Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition.
    Zhao N; Powell RT; Yuan X; Bae G; Roarty KP; Stossi F; Strempfl M; Toneff MJ; Johnson HL; Mani SA; Jones P; Stephan CC; Rosen JM
    Nat Commun; 2021 Jul; 12(1):4262. PubMed ID: 34253738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.